GreenLight Biosciences, Inc.
200 Boston Avenue
About GreenLight Biosciences, Inc.
GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible.
GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection and support the health of bees and other pollinators. The GreenLight team values diversity, inclusion, and equality and promises to use collaboration to remain scientifically imaginative and passionately focused on making a difference in the world.
23 articles with GreenLight Biosciences, Inc.
Here’s a look at a few of the industry expansions that have been announced so far this month.
GreenLight Biosciences opens RNA production facility for the next generation of agricultural products
GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, announced the opening of its manufacturing plant in Rochester, New York, Bloomberg reports.
GreenLight Biosciences, Inc. announced the appointment of Jennifer Raymond as SVP, CMC Manufacturing today.
8/11/2021Check out where the money went in the life sciences industry this week.
Messenger RNA has become the life sciences hero of the decade. The lynchpin in the fight against COVID-19, companies are taking mRNA technology to new heights.
GreenLight Biosciences today announced that they have acquired rights to portions of Bayer's topical RNA Intellectual Property portfolio. These assets include bee health capabilities to protect against Varroa mites, a major threat to honeybees.
GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, today announced the appointment of Amin Khan as the company's Chief Scientific Officer, Human Health.
GreenLight Biosciences today published its Blueprint to Vaccinate the World. This plan lays out how the world can quickly end the Covid pandemic by investing in a global network of seven vaccine manufacturing plants.
GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design and manufacturing for human, animal and plant health, announced the appointment of Mark Singleton as the company's Senior Vice President of Technology and External Innovation.
GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design and manufacturing for human, animal and plant health, announced the appointment of Thomas Crampton as the company's Senior Vice President for Corporate Affairs.
Manufacturing capacity is often decried as a major bottleneck in administering COVID-19 vaccines to a global population of 7.8 billion. For mRNA vaccines, the bottleneck is the availability of raw materials, not bioreactors.
GreenLight Biosciences, Inc. , an integrated life sciences company developing RNA-based products for plant health, human health and animal health, today announced Charu Manocha as the company's new Chief People Officer.
GreenLight Biosciences Receives $3.3 Million Grant to Develop Sickle Cell Disease Cure Using mRNA Gene Therapy
GreenLight Biosciences has received a $3.3 million grant from the Bill & Melinda Gates Foundation to develop new mRNA-based gene therapies for Sickle Cell Disease and other global health challenges. The funding will support GreenLight's research and testing of affordable therapies using the company's novel messenger RNA (m
GreenLight Biosciences supercharges its efforts with $102M Series D funding from top-tier investors including Morningside Ventures, S2G Ventures and Lupa Systems
GreenLight Biosciences today announced it has raised an oversubscribed $102 million round of funding from new and existing investors to rapidly expand production of its RNA products for agricult
GreenLight Biosciences closed an oversubscribed $17 million “special purpose funding round” in order to expand its scalable mRNA manufacturing capability for its mRNA COVID-19 vaccine. The goal is to be able to produce billions of doses.
GreenLight Biosciences raises $17M financing round to accelerate large-scale manufacturing of future COVID-19 vaccines
GreenLight Biosciences today announced it has closed an oversubscribed $17M special purpose funding round from new and existing investors to build out its scalable mRNA production capability targeting the production of billions of doses of COVID-19 vaccine
As part of its expansion into human health, GreenLight Biosciences, Inc. is pleased to welcome the first members of its new Life Sciences Advisory Board.
Represents the Highest Recognition Awarded by the Mexican Senate
He has over 20 years of global agriculture sales, marketing, business development and business leadership experience with Syngenta and DuPont.
Unique Cell-Free Bioproduction Platform delivers cost effective, high quality RNA solutions to human, animal and crop challenges